Insider Selling: Acceleron Pharma Inc (XLRN) CEO Sells 12,675 Shares of Stock

Share on StockTwits

Acceleron Pharma Inc (NASDAQ:XLRN) CEO Habib J. Dable sold 12,675 shares of the business’s stock in a transaction that occurred on Tuesday, December 4th. The shares were sold at an average price of $52.99, for a total transaction of $671,648.25. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Acceleron Pharma stock opened at $48.19 on Friday. The company has a market capitalization of $2.26 billion, a PE ratio of -17.98 and a beta of 1.53. Acceleron Pharma Inc has a twelve month low of $32.53 and a twelve month high of $59.59.

Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.66) by $0.03. The company had revenue of $3.30 million during the quarter, compared to analysts’ expectations of $4.37 million. Acceleron Pharma had a negative net margin of 807.36% and a negative return on equity of 32.69%. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.65) earnings per share. Sell-side analysts expect that Acceleron Pharma Inc will post -2.51 EPS for the current fiscal year.

XLRN has been the subject of a number of analyst reports. BidaskClub upgraded shares of Acceleron Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, August 28th. Morgan Stanley assumed coverage on shares of Acceleron Pharma in a report on Monday, September 10th. They issued an “equal weight” rating and a $55.00 price target for the company. Piper Jaffray Companies upgraded shares of Acceleron Pharma from a “neutral” rating to an “overweight” rating and upped their price target for the company from $52.00 to $75.00 in a report on Monday, September 17th. Cann reiterated a “hold” rating on shares of Acceleron Pharma in a report on Wednesday, October 31st. Finally, HC Wainwright reiterated a “buy” rating and issued a $72.00 price target on shares of Acceleron Pharma in a report on Monday, December 3rd. Six equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $56.20.

Several hedge funds have recently made changes to their positions in the company. FMR LLC lifted its position in shares of Acceleron Pharma by 56.6% in the third quarter. FMR LLC now owns 6,900,369 shares of the biopharmaceutical company’s stock worth $394,909,000 after purchasing an additional 2,494,546 shares in the last quarter. BlackRock Inc. lifted its position in shares of Acceleron Pharma by 3.4% in the third quarter. BlackRock Inc. now owns 4,347,892 shares of the biopharmaceutical company’s stock worth $248,830,000 after purchasing an additional 142,823 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Acceleron Pharma by 33.0% in the third quarter. Vanguard Group Inc. now owns 3,425,363 shares of the biopharmaceutical company’s stock worth $196,034,000 after purchasing an additional 849,608 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Acceleron Pharma by 13.1% in the third quarter. Janus Henderson Group PLC now owns 1,394,256 shares of the biopharmaceutical company’s stock worth $79,793,000 after purchasing an additional 161,049 shares in the last quarter. Finally, Brown Advisory Inc. lifted its position in shares of Acceleron Pharma by 3.5% in the third quarter. Brown Advisory Inc. now owns 530,353 shares of the biopharmaceutical company’s stock worth $30,353,000 after purchasing an additional 18,147 shares in the last quarter. 95.78% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Insider Selling: Acceleron Pharma Inc (XLRN) CEO Sells 12,675 Shares of Stock” was originally reported by BBNS and is owned by of BBNS. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://baseballnewssource.com/2018/12/08/insider-selling-acceleron-pharma-inc-xlrn-ceo-sells-12675-shares-of-stock/3063973.html.

Acceleron Pharma Company Profile

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

Featured Article: Retained Earnings

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.